Abstract 5495
Background
Digital biomarkers allow for continuous remote patient monitoring and will potentially change the way healthcare is provided and clinical trials are designed. We conducted a study to identify current preferences and interest in digital biomarkers in patients with advanced urological cancers.
Methods
We included 80 patients undergoing systemic therapy for advanced urologic malignancies at our institution. A questionnaire was developed to survey the current access to online information and digital technologies and to rate preferences on a scale from 1 (does not apply) to 5 (fully applies). Statistical analysis was performed by Chi-square test and unpaired t-test.
Results
26% of the cohort presented with prostate cancer (PC), 38% with urothelial cancer (UC) and 36% with renal cell carcinoma (RCC). 69% of patients researched medical information about their disease online, 85% of PC patients, 72% of RCC patients, and 53% of UC respectively. 63% of all patients use smartphones and 9% wearables. Smartphone usage is most common in RCC patients (76%) followed by PC (66%) and UC (46%) patients while wearables are used by 7% of RCC, 5% of PC, and 13% of UC patients, respectively. In our cohort RCC patients are younger (Mean 63.3 years) than PC patients (Mean 69.3 years) and UC patients (Mean 68.3 years). The percentage of patients seeking information online and using smartphones or wearables is significantly higher in patients under the age of 75 (p < 0.05). With respect to the information generated by wearables, patients’ interest in activity data is significantly higher (3.5/5) than interest in sleeping profiles (2.5/5; p < 0.01). Patients are more likely to use wearables in clinical trials when they have access to the generated activity data (2.8/5) than using them without gaining access to the information (2.1/5; p < 0.01). Interest in wearable data and willingness to wear them as part of clinical trials are significantly higher for male gender (p < 0.01), and is independent of age and distance between home and the clinical trial site.
Conclusions
Our study demonstrates a high engagement of patients in digital technologies. Even though there is a lower penetration rate for digital technologies in older people, interest in digital biomarker data is high in regardless of age group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Severin Rodler.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2344 - Lung Cancer in Europe: strengthening policy responses to address unmet needs
Presenter: Mary Bussell
Session: Poster Display session 3
Resources:
Abstract
1359 - Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage
Presenter: Selina Wong
Session: Poster Display session 3
Resources:
Abstract
4433 - Acute Diagnostic Oncology Clinic: A Unique Primary Care-Oncology Service
Presenter: Abhijit Gill
Session: Poster Display session 3
Resources:
Abstract
3506 - THE NEW MUTATIONAL MODEL IN ONCOLOGY. What changes in welfare, clinical practice, research, and regulatory procedures
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3350 - Selection of a set of quality indicators (QI) for oncological clinical pathway
Presenter: Aude Fourcade
Session: Poster Display session 3
Resources:
Abstract
4400 - Sustainable drug prices at market launch: policy proposals and their empirical evidence
Presenter: Nora Fanzen
Session: Poster Display session 3
Resources:
Abstract
4118 - Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)
Presenter: Nathalie Olympios
Session: Poster Display session 3
Resources:
Abstract
1340 - The direct medical cost of breast cancer in a Belgian hospital
Presenter: Hannan Lemhouer
Session: Poster Display session 3
Resources:
Abstract
1863 - Does the healthcare system approaches cancer patients for using private services during diagnostic process?
Presenter: Karolina Osowiecka
Session: Poster Display session 3
Resources:
Abstract
2637 - Measuring financial toxicity of cancer in the Italian health care system: initial results of the patient reported outcome for Fighting Financial Toxicity of cancer project (proFFiT).
Presenter: Silvia Riva
Session: Poster Display session 3
Resources:
Abstract